The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection

摘要: Abstract In patients with metastatic colorectal cancer (mCRC) predominantly confined to the liver, whether a patient undergoes potentially curative resection of liver lesions is well-established principal determinant long-term survival. There are number different agents, both chemotherapeutic and targeted biologic which can aid in shrinking tumors, would have otherwise been unresectable, allowing for resection. The aim this review article summarize available evidence regarding optimal therapeutic strategies converting initially unresectable metastases resection; we do not discuss who present resectable disease. We taken approach review trials that included R0 rates as one study endpoints specifically enrolled liver-limited Primary tumor location has recently emerged putative prognostic predictive factor mCRC; however, presently, there lack resectability outcomes differentiating location–defined subgroups, several ongoing retrospective analyses anticipated guide insights future. conclusion, RAS wild-type mCRC, data support preferential use anti-epidermal growth receptor monoclonal antibody cetuximab when combined standard-of-care infusional doublet chemotherapy regimens (FOLFOX or FOLFIRI) conversion Furthermore, involving intensified (i.e., 3-drug backbones such FOLFOXIRI without agent) promote